Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Maastricht Radiation Oncology
Information provided by (Responsible Party):
Maastricht Radiation Oncology Identifier:
First received: July 19, 2010
Last updated: September 27, 2016
Last verified: September 2016
Our group has shown that increasing the radiation dose to pre-specified normal tissue dose constraints could lead to increased TCP with the same NTCP in patients with non-concurrent and concurrent chemo-radiation. Here, the investigators want to investigate its efficacy in a prospective study in patients with stage I-III NSCLC, who are selected for high-dose radiotherapy with or without chemotherapy, but treated with IMRT. The latter technique has become standard, but the patterns of recurrence and the possibility for dose-escalation in an individualised setting have never been investigated properly.

Condition Intervention Phase
Stage I-III Non-small Cell Lung Cancer
Radiation: Radiotherapy
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With IMRT for Stage I-III Non-small Cell Lung Cancer to an Individualised MLD

Resource links provided by NLM:

Further study details as provided by Maastricht Radiation Oncology:

Primary Outcome Measures:
  • Overall survival [ Time Frame: 2.3 and 5 years ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: 2.3 and 5 years ]
  • Dyspnea (CTCAE 4.0) [ Time Frame: 2.3 and 5 years ]
  • Dysphagia (CTCAE 4.0) [ Time Frame: 2.3 and 5 years ]
  • Patterns of recurrence [ Time Frame: 2.3 and 5 years ]

Estimated Enrollment: 300
Study Start Date: May 2009
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single group Radiation: Radiotherapy

Detailed Description:

Eligible patients (see below) will receive radiotherapy to the primary tumor and the initially involved mediastinal lymph nodes to an MLD (Mean Lung Dose) of 20 +/-1Gy, irrespective of lung function.

Other dose-constraints: spinal cord max: 54Gy, brachial plexus (Dmax):66Gy

In concurrence with chemotherapy, radiotherapy will be delivered as follows:

  • First three weeks/30 fractions: twice-daily fractions of 1.5Gy, with 8h to 10h as interfraction interval, 5 days per week. Total dose: 45Gy/30 fractions
  • Thereafter: once daily fractions of 2.0Gy, 5 days per week until the target dose has been reached.

In sequential or radiotherapy alone schedules, twice-daily 1.8Gy with an interfraction interval of at least 8h will be delivered.

The radiation doses will be specified according to ICRU 50. Lung density corrections will be applied, as well as all standard QA procedures. Technical requirements are the same as in standard practice at MAASTRO clinic

Chemotherapy schedules allowed:

  1. 1-2 cycles induction chemotherapy: any third generation schedule is allowed. The type will be registered.
  2. Concurrent part: (day 1 = first day of radiotherapy)

    • cisplatin - vinorelbine
    • cisplatin - docetaxel
    • cisplatin - etoposide
    • cisplatin - pemetrexed in non-squamous histologies Q 3 weeks; 3 cycles

When the calculated creatinin clearance is less than 60ml/min, cisplatin may be substituted for carboplatin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytological proven NSCLC
  • IUCC stage I-III, or solitary metastases (<6), which are amendable for radical local treatment.
  • Performance status 0-2
  • IMRT technique

Exclusion Criteria:

  • Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)
  • Stage IV, except for solitary (<6) metastases
  • Performance status 3 or more
  • No IMRT technique
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01166204

MAASTRO clinic Recruiting
Maastricht, Limburg, Netherlands, 6229 ET
Contact: Dirk De Ruysscher, MD, PhD    +31 88 44 55 700   
Contact: Chantal Overhof    +31 88 44 55 686   
Principal Investigator: Dirk De Ruysscher, MD, PhD         
Sponsors and Collaborators
Maastricht Radiation Oncology
  More Information

Responsible Party: Maastricht Radiation Oncology Identifier: NCT01166204     History of Changes
Study First Received: July 19, 2010
Last Updated: September 27, 2016

Keywords provided by Maastricht Radiation Oncology:

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on April 21, 2017